By Fineline Cube 
China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group (HKG: 1093), has filed a patent review petition with the U.S. Patent and Trademark Office (USPTO). The petition challenges the validity of claims 1-9, 12-17, and 21-25 of Ascletis’ granted GLP-1-related patent (U.S. Patent No. US12234236B1), which remains under USPTO examination.
Patent Details
The patent in question pertains to Ascletis’ proprietary technology used in its GLP-1R agonist candidate ASC30. Ascletis received the patent grant from the USPTO in February 2025. Conjupro Bio’s patent application (Application No.: PCT/CN2024/140920) shares identical molecular structures with those covered by Ascletis’ already granted patent. Ascletis filed its patent application with the USPTO over three months prior to CSPC’s submission.
Company Response
Ascletis revealed that in late March 2025, it received an unsolicited global licensing proposal from CSPC regarding the GLP-1R agonist compound covered by this patent, which Ascletis subsequently declined. The company expressed full confidence in the patent’s validity and stated its commitment to employing all necessary legal measures to defend its intellectual property rights if CSPC proceeds with the patent review.-Fineline Info & Tech